DiaSorin DiaSorin Gets FDA 510(k) Clearance for Molecular CMV Test The test, which runs on the company's Liaison MDx system, is designed for use with both saliva swab and urine specimens from newborns 21 days old or younger. DiaSorin Q3 Revenues Dip 5 Percent as COVID-19 Test Sales Fall The firm said revenue is still up for the first nine months year-over-year on strong non-COVID immunodiagnostics and molecular diagnostics sales. DiaSorin Gets $31M BARDA Funding for Point-of-Care Instrument The Italian firm said the Liaison NES will help improve access to testing for bacterial and viral diseases through an easy-to-use instrument running lower cost assays. DiaSorin Gains FDA 510(k) Clearance for COVID-19 PCR Test The assay is one of a few that have received full FDA clearance for COVID-19, which the agency has been encouraging companies to pursue. DiaSorin Posts 32 Percent Jump in Q2 Revenues The revenue growth was driven by higher sales of non-COVID-19 molecular diagnostic and immunodiagnostic products. May 20, 2022 Luminex Obtains CE Marking for MDx Panel to Detect Flu A/B, RSV, COVID-19 May 6, 2022 DiaSorin Q1 Revenues Rise 34 Percent Despite Dip in COVID-19 Test Demand Mar 17, 2022 DiaSorin Expects 2022 Revenue Growth From Base Business, Luminex as COVID-19 Testing Declines Premium Mar 16, 2022 DiaSorin 2021 Revenues Rise 41 Percent on SARS-CoV-2, Luminex Sales Growth Feb 1, 2022 Genetic Analysis Receives CE Mark for Microbiome Test on Luminex Magpix Instrument Nov 11, 2021 DiaSorin Q3 Revenues Rise 51 Percent on Luminex Acquisition, Recovery of Non-COVID Test Sales Sep 20, 2021 DiaSorin Molecular Receives CE Mark for Multiplex COVID-19, Influenza Test Jul 30, 2021 DiaSorin Q2 Revenues Rise 20 Percent on SARS-CoV-2 Testing Demand May 14, 2021 DiaSorin Q1 Revenues Rise 53 Percent on SARS-CoV-2 Testing Demand Apr 13, 2021 With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence Premium Apr 12, 2021 DiaSorin to Acquire Luminex for $1.8B Feb 25, 2021 Luminex Shares Surge on Rumor of Acquisition by DiaSorin Jan 13, 2021 BARDA Provides Additional Funding to DiaSorin Molecular for COVID-19 Tests Sep 17, 2020 DiaSorin Receives CE Mark to Use Saliva Samples With COVID-19 Test Sep 8, 2020 FDA Clears DiaSorin Test for Influenza, RSV Jul 7, 2020 DiaSorin Molecular Gets CE Mark for Flu, RSV Assay Jun 15, 2020 DiaSorin Molecular Gets CE Mark for Congenital CMV Assay Apr 13, 2020 Coronavirus Tests From Seegene, DiaSorin, Others Get Health Canada Approval Mar 20, 2020 Coronavirus Test From DiaSorin Molecular Gets FDA Emergency Use Authorization Mar 13, 2020 DiaSorin Molecular Awarded $679K BARDA Funding to Develop Coronavirus Test Load More Breaking News Simple HealthKit Raises $8M in Series A Round Top Five Articles on GenomeWeb Last Week: Quantum-Si Layoffs, UBS Coverage Initiations, More LumiraDx Secures FDA Emergency Use Authorization, UK Approval for COVID-19, Flu Test Rarity Bioscience Raises Additional €500,000 Cancer Prognoses Informed by Module-Based Approach, Study Finds The Scan UK Team Presents Genetic, Epigenetic Sequencing Method Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers. DNA Biobank Developed for French Kidney Donors, Recipients The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France. Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site. Study Reveals New Details About Genetics of Major Cause of Female Infertility Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.